<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7779730</article-id><article-id pub-id-type="pmc">2033834</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ellis</surname><given-names>P. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Talbot</surname><given-names>D. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nicolson</surname><given-names>M. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Priest</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ashley</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>I. E.</given-names></name></contrib></contrib-group><aff>Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK.</aff><pub-date pub-type="ppub"><month>6</month><year>1995</year></pub-date><volume>71</volume><issue>6</issue><fpage>1315</fpage><lpage>1318</lpage><abstract><p>A pilot study of continuous infusional 5-fluorouracil 200 mg m-2 per 24 h by ambulatory pump and Hickman line for the entire treatment cycle with mitomycin C 8 mg m-2 i.v. on day 1 and cisplatin 75 mg m-2 i.v. on day 1, both repeated every 28 days, was carried out in 31 previously untreated patients with advanced non-small-cell lung cancer (NSCLC). Of 31 patients assessable for response, one attained a complete remission and eight a partial remission, an overall response rate of 29%. Haematological toxicity was minimal, with only 3% of patients developing WHO grade III/IV neutropenia and 13% grade III/IV thrombocytopenia. Significant side-effects included moderate to severe emesis (41%), mucositis (34%), diarrhoea (31%) and palmar-plantar syndrome (14%). Seven patients (23%) had Hickman line complications requiring line removal. Continuous infusional chemotherapy with this regimen is active in advanced non-small-cell lung cancer, but its complexity and associated treatment toxicity offer little advantage over equally active but simpler and less toxic cisplatin-based regimens.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00052-0195.tif" xlink:title="scanned-page" xlink:role="1315" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00052-0196.tif" xlink:title="scanned-page" xlink:role="1316" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00052-0197.tif" xlink:title="scanned-page" xlink:role="1317" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00052-0198.tif" xlink:title="scanned-page" xlink:role="1318" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

